Dr Reddy’s shares in focus after This fall web revenue tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in
The corporate launched its leads to the post-market hours of Tuesday. Its income from operations, in the meantime, fell 12% YoY to Rs 7,516 crore throughout the quarter below evaluate, from Rs 8,506 crore reported within the corresponding quarter of the earlier monetary yr.
The decline in quarterly earnings was totally on account of diminished gross sales of Lenalidomide, worth erosion in North America and Europe Generics and a one-time SSA impression.
Together with the This fall outcomes, Dr Reddy’s Laboratories advisable a last dividend of Rs 8 per fairness share for the monetary yr 2026, topic to shareholders’ approval at its upcoming Annual Normal Assembly (AGM). The document date to find out the eligibility of shareholders set to obtain dividend has been mounted on July 10.
Morgan Stanley on Dr Reddy’s Laboratories
Morgan Stanley maintained its ‘Equal-weight’ ranking on the shares of Dr Reddy’s Laboratories, however diminished its goal worth to Rs 1,215 apiece. This means a draw back potential of greater than 4% from the inventory’s earlier closing worth of Rs 1,270 apiece on NSE.
The worldwide brokerage famous that the corporate’s adjusted This fall income and EBITDA missed estimates by 2% and 13% respectively, with semaglutide ramp-up barely delayed because the agency awaits Brazil’s approval, ET Now reported. It added that the administration now expects 6-7 million pen gross sales in 2026, and greater than 40 million capability by FY28.
Morgan Stanley highlighted that the corporate’s US enterprise is stabilising publish gRevlimid launch with double-digit FY27 development steerage. It reduce FY27/28 EPS estimates by 3% and three.5% respectively, because it sees execution dangers and weak US generics backdrop protecting margin outlook subdued.
Goldman Sachs on Dr Reddy’s Laboratories
Goldman Sachs maintained its ‘Promote’ ranking on the shares of Dr Reddy’s Laboratories, and diminished its goal worth to Rs 1,050 apiece. This means a draw back potential of greater than 17% from the inventory’s earlier closing worth.The worldwide brokerage highlighted that This fall income and EBITDA margin missed estimates amid decrease lenalidomide gross sales, with one-time shelf inventory changes impacting profitability, ET Now reported. It revised FY27-28 EPS estimates by -9% to +3%.
Goldman Sachs is anxious in regards to the total gOzempic alternative in Canada, and sees a skinny near-to-medium time period pipeline for larger worth merchandise, the report additional mentioned. It sees key base enterprise merchandise dealing with intense worth erosion.
Sensex, Nifty as we speak: Catch all of the LIVE inventory market motion right here
(Disclaimer: Suggestions, solutions, views and opinions given by the consultants are their very own. These don’t characterize the views of The Financial Instances)
